Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Their lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.

Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Michael J. Fox Foundation

Pfizer Venture Investments

Mission BioCapital

Atlas Venture

Tekla Capital Management

Pivotal bioVenture Partners

Surveyor Capital

Cormorant Asset Management

Eli Lilly

This week at the Alzheimer's Association® International Conference, Arkuda Therapeutics will present preclinical data on lead development candidate ARKD-104, a novel oral therapeutic in development for the treatment of GRN-related frontotemporal dementia. The study showed treatment with ARKD-104 markedly increased progranulin levels – critical to restoring lysosomal function in not only FTD-GRN but in other neurodegenerative diseases. Learn more: https://lnkd.in/enX_JJcg

#progranulin #granulin #lysosome #endFTD #Alzheimers

Congrats to Thomas Kukar's lab (+ Arkuda team members Chris Holler, Ph.D., Bonne Thompson, Giuseppe Astarita, and Jean-François Blain) on this critically important work demonstrating the important role that granulins play in FTD. 

The team at Arkuda Therapeutics continues to advance drug candidates which modulate both progranulin and granulins towards clinical studies, with the goal of someday offering novel treatments for FTD and other neurodegenerative diseases. 

#granulins #ftd #therapeutics #neurodegeneration #neurodegenerativediseases

https://lnkd.in/gmEx-CQb

Congratulations to Raymond Hurst and the rest of the Arkuda Therapeutics team for a great presentation at #adpd2023, "Therapeutic Potential of ARKD-104 for Treatment of Frontotemporal Dementia and Other Neurodegenerative Diseases"

Wishing everyone a happy International Women's Day!

Today and every day we celebrate the incredible achievements of women in different aspects of life all over the world.  We are committed to an inclusive workplace which recognizes the importance of collective activism in driving sustainable change, and aspire towards a world in which we all #EmbraceEquity.

 #IWD2023

msh id	COM:ARKUDATX
symbol	-
name	Arkuda Therapeutics
homepage url	https://arkudatx.com
country	US
sector	Healthcare
industry	Biotechnology
market	PRIVATE
employee count	28
crunchbase url	https://www.crunchbase.com/organization/arkuda-therapeutics
linkedin url	https://www.linkedin.com/company/arkudatx
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	16.65
growth score 28	22.85
growth score 90	53.03
growth score 365	73.61

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:ARKUDATX

Arkuda Therapeutics

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-